Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REBECCA L MOROOSE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1972503159
CMS profile
362319
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$112,144.11

149 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $70,505.76 114
Seagen Inc. $20,206.43 22
Immunomedics, Inc. $13,772.14 9
PFIZER INC. $3,312.28 2
Novartis Pharmaceuticals Corporation $2,947.50 1
Eli Lilly Export S.A. Puerto Rico Branch $1,400.00 1

Page 1 of 3; records 1–50 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REBECCA L MOROOSE

NPI 1972503159 · CMS profile ID 362319

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972503159?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972503159?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972503159?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
REBECCA L MOROOSE, NPI 1972503159, CMS profile ID 362319, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 149 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1972503159?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

149 matching records · $112,144.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 149 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 149.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Seagen Inc. $920.0012/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433901 CMS
Immunomedics, Inc. $1,250.0012/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658657 CMS
Lilly USA, LLC $1,400.0012/15/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728610913 CMS
Immunomedics, Inc. $4,000.0012/10/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658653 CMS
Immunomedics, Inc. $66.4212/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658655 CMS
Novartis Pharmaceuticals Corporation $2,947.5012/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753370707 CMS
Immunomedics, Inc. $4,000.0012/02/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658649 CMS
Immunomedics, Inc. $114.4712/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658651 CMS
Immunomedics, Inc. $591.2512/02/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658839 CMS
PFIZER INC. $2,750.0011/16/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743575649 CMS
Seagen Inc. $1,030.0011/08/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433893 CMS
Eli Lilly Export S.A. Puerto Rico Branch $1,400.0010/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728627763 CMS
Seagen Inc. $1,030.0010/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433897 CMS
Seagen Inc. $1,030.0010/26/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433831 CMS
Immunomedics, Inc. $1,250.0010/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658647 CMS
Immunomedics, Inc. $1,250.0010/22/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658645 CMS
Immunomedics, Inc. $1,250.0010/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750658643 CMS
Lilly USA, LLC $1,400.0010/09/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728614269 CMS
Lilly USA, LLC $1,400.0009/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728624325 CMS
Seagen Inc. $920.0009/29/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433885 CMS
Lilly USA, LLC $3,325.0009/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728610895 CMS
Lilly USA, LLC $1,400.0009/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728627777 CMS
Seagen Inc. $124.6909/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433803 CMS
Seagen Inc. $16.6809/23/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433807 CMS
Seagen Inc. $2,945.0009/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433811 CMS
Seagen Inc. $1,840.0009/22/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433737 CMS
Lilly USA, LLC $1,400.0009/01/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728604497 CMS
Lilly USA, LLC $1,400.0008/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728627773 CMS
Lilly USA, LLC $1,925.0008/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728627775 CMS
Seagen Inc. $56.2508/27/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433787 CMS
Seagen Inc. $690.0007/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433713 CMS
Seagen Inc. $690.0006/02/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433695 CMS
Seagen Inc. $920.0004/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433881 CMS
Lilly USA, LLC $161.2103/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728617549 CMS
Lilly USA, LLC $404.3003/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728617565 CMS
Lilly USA, LLC $446.5403/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728621059 CMS
Lilly USA, LLC $221.0003/25/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728627753 CMS
Lilly USA, LLC $2,800.0003/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728607509 CMS
Lilly USA, LLC $15.0003/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728607513 CMS
Lilly USA, LLC $10.0003/23/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728614267 CMS
Lilly USA, LLC $20.7003/23/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728617571 CMS
Lilly USA, LLC $13.9903/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728627771 CMS
Lilly USA, LLC $2,450.0003/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728607511 CMS
Lilly USA, LLC $2,800.0003/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728610911 CMS
Lilly USA, LLC $80.8603/16/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728604495 CMS
Lilly USA, LLC $5.0003/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728610905 CMS
Lilly USA, LLC $413.9503/16/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728610907 CMS
Lilly USA, LLC $10.3603/16/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728610909 CMS
Lilly USA, LLC $20.0003/16/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728614265 CMS
Lilly USA, LLC $15.0003/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728624323 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $144,632.89 194
PY2020 $112,144.11 149
PY2021 $126,523.25 106
PY2022 $157,739.91 136
PY2023 $1,619.58 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,773.40 2
PY2025 Principal investigator $23,429.00 2
PY2024 Recipient $3,047.65 1
PY2023 Recipient $4,115.87 1
PY2023 Principal investigator $488.00 1
PY2022 Principal investigator $30,225.68 18
PY2021 Recipient $3,820.00 2
PY2021 Principal investigator $107,576.56 28
PY2020 Principal investigator $105,271.83 68
PY2019 Principal investigator $147,188.91 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $530.00 12/23/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 742901773
Principal investigator 1 Seagen Inc. $219.00 12/22/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454825
Principal investigator 1 Seagen Inc. $842.00 12/22/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454827
Principal investigator 1 Seagen Inc. $3,340.00 12/22/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454831
Principal investigator 1 PFIZER INC. $1,000.00 12/10/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742897347
Principal investigator 1 PFIZER INC. $1,000.00 12/10/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742897349
Principal investigator 1 PFIZER INC. $1,000.00 12/10/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742897353
Principal investigator 1 Seagen Inc. $20.00 11/24/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454821
Principal investigator 1 Seagen Inc. $76.00 11/24/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454823
Principal investigator 1 Seagen Inc. $876.00 11/24/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454829
Principal investigator 1 Seagen Inc. $3,369.00 11/24/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454833
Principal investigator 1 PFIZER INC. $29.59 11/13/2020 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742886395
Principal investigator 1 PFIZER INC. $45.00 11/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742883333
Principal investigator 1 Seagen Inc. $5,010.00 10/23/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454835
Principal investigator 1 PFIZER INC. $45.00 10/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742883329
Principal investigator 1 Seagen Inc. $2,122.00 09/25/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454785
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,055.60 09/22/2020 Covered Recipient Teaching Hospital
ORLANDO HEALTH
TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN THE TREATMENT OF MEN AND POSTMENOPAUSAL WOMEN WITH HR PLUS HER2 LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON No dispute reported 06/30/2026 721488211
Principal investigator 1 PFIZER INC. $2,923.66 09/10/2020 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742886401
Principal investigator 1 PFIZER INC. $45.00 09/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742883689
Principal investigator 1 Seagen Inc. $2,122.00 08/26/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454787
Principal investigator 1 PFIZER INC. $100.00 08/20/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 742928627
Principal investigator 1 PFIZER INC. $45.00 08/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742883685
Principal investigator 1 Seagen Inc. $6,680.00 07/27/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454789
Principal investigator 1 PFIZER INC. $1,197.33 07/09/2020 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742887027
Principal investigator 1 PFIZER INC. $15.00 07/08/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742931945
Principal investigator 1 PFIZER INC. $45.00 07/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742882595
Principal investigator 1 Seagen Inc. $4.00 06/25/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454545
Principal investigator 1 Seagen Inc. $14.00 06/25/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454547
Principal investigator 1 Seagen Inc. $2.00 06/25/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454549
Principal investigator 1 Seagen Inc. $7.00 06/25/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454551
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $10,754.00 06/24/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY-US, INC
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ No dispute reported 06/30/2026 749645253
Principal investigator 1 PFIZER INC. $15.00 06/02/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742923615
Principal investigator 1 PFIZER INC. $15.00 06/02/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742924833
Principal investigator 1 PFIZER INC. $45.00 06/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742882601
Principal investigator 1 Seagen Inc. $6,680.00 05/28/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454553
Principal investigator 1 PFIZER INC. $431.00 05/04/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742952247
Principal investigator 1 PFIZER INC. $431.00 05/04/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742952290
Principal investigator 1 PFIZER INC. $431.00 05/04/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742952293
Principal investigator 1 PFIZER INC. $45.00 05/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742883687
Principal investigator 1 PFIZER INC. $15.00 04/29/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742923555
Principal investigator 1 PFIZER INC. $15.00 04/29/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742923617
Principal investigator 1 PFIZER INC. $2,306.66 04/15/2020 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742886985
Principal investigator 1 PFIZER INC. $45.00 04/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742882599
Principal investigator 1 PFIZER INC. $15.00 03/24/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742967385
Principal investigator 1 PFIZER INC. $15.00 03/24/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742967915
Principal investigator 1 PFIZER INC. $1,535.00 03/17/2020 Non-covered Recipient Entity
TRIO US INC
A PHASE I OPENLABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB MDV3800 IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT No dispute reported 06/30/2026 742886873
Principal investigator 1 PFIZER INC. $6,903.33 03/17/2020 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742886877
Principal investigator 1 PFIZER INC. $1,530.00 03/17/2020 Non-covered Recipient Entity
TRIO US INC
A PHASE I OPENLABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB MDV3800 IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT No dispute reported 06/30/2026 742886989
Principal investigator 1 PFIZER INC. $1,002.00 03/12/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742974115
Principal investigator 1 PFIZER INC. $1,002.00 03/12/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742974755
Principal investigator 1 PFIZER INC. $1,002.00 03/12/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742974760
Principal investigator 1 PFIZER INC. $1,002.00 03/12/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742974819
Principal investigator 1 PFIZER INC. $1,000.00 03/02/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGYUS INC
A SINGLEARM OPENLABEL MULTICENTER EXTENDED TREATMENT SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB No dispute reported 06/30/2026 742974825
Principal investigator 1 PFIZER INC. $45.00 03/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742886015
Principal investigator 1 PFIZER INC. $50.00 02/20/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PHASE 3 TRIAL OF FULVESTRANT FASLODEX REGISTERED WITH OR WITHOUT PD0332991 PALBOCICLIB GOSERELIN IN WOMEN WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPY No dispute reported 06/30/2026 742972151
Principal investigator 1 PFIZER INC. $11.00 02/19/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742967855
Principal investigator 1 PFIZER INC. $11.00 02/19/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742967885
Principal investigator 1 PFIZER INC. $1,109.33 02/13/2020 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742886841
Principal investigator 1 PFIZER INC. $1,000.00 02/13/2020 Non-covered Recipient Entity
TRIO US INC
A PHASE 3 OPENLABEL RANDOMIZED PARALLEL2ARMMULTICENTER STUDY OF TALAZOPARIBBMN 673 VERSUS PHYSICIANS CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED ANDOR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE No dispute reported 06/30/2026 742886983
Principal investigator 1 PFIZER INC. $45.00 02/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742885989
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,302.00 01/30/2020 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY INC
MONALEESA 3 A RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED STUDY OF RIBOCICLIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHO HAVE RECEIVED NO OR ONLY ONE LINE No dispute reported 06/30/2026 721496171
Principal investigator 1 Seagen Inc. $8,550.00 01/29/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454593
Principal investigator 1 PFIZER INC. $1,197.33 01/28/2020 Non-covered Recipient Entity
TRIO US INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742886398
Principal investigator 1 PFIZER INC. $2,820.00 01/28/2020 Non-covered Recipient Entity
TRIO US INC
A PHASE I OPENLABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB MDV3800 IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF HEPATIC IMPAIRMENT No dispute reported 06/30/2026 742886879
Principal investigator 1 PFIZER INC. $11.00 01/22/2020 Non-covered Recipient Entity
Orlando Health Inc
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742967883
Principal investigator 1 Seagen Inc. $219.00 01/08/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454589
Principal investigator 1 Seagen Inc. $842.00 01/08/2020 Non-covered Recipient Entity
UF HEALTH CANCER CENTER AT ORLANDO HEALTH
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib No dispute reported 06/30/2026 733454591
Principal investigator 1 PFIZER INC. $45.00 01/01/2020 Non-covered Recipient Entity
ORLANDO HEALTH INC
A RANDOMIZED MULTICENTER DOUBLEBLIND PHASE 3 STUDY OF PD0332991 ORAL CDK 46 INHIBITOR PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER HER2 BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE No dispute reported 06/30/2026 742886011